Upgrade to SI Premium - Free Trial

AstraZeneca (AZN) Confirms FDA Partial Clinical Hold Placed on Patient Recruitment for MEDI4736 Trial in HNSCC; Issues Commentary

October 27, 2016 2:47 PM
AstraZeneca (NYSE: AZN) issued the following statement following news that recruitment for its study of MEDI4736 (Durvaluma) in head and ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Corporate News FDA

Next Articles